Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All

Published:2018-03 Issue:3 Volume:4 Page:197-206
ISSN:2405-8033
Container-title:Trends in Cancer
language:en
Short-container-title:Trends in Cancer

Author:

Shah Bijal,Zhao Xiaohong,Silva Ariosto S.,Shain Kenneth H.,Tao Jianguo^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference63 articles.

1. Toward new treatments for mantle-cell lymphoma?;Zucca;N. Engl. J. Med.,2013

2. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N. Engl. J. Med.,2013

3. The B-cell receptor signaling pathway as a therapeutic target in CLL;Woyach;Blood,2012

4. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma;Chiron;Cancer Discov.,2014

5. A preclinical assay for chemosensitivity in multiple myeloma;Khin;Cancer Res.,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs;Cancer Letters;2024-09

2. Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas;Acta Pharmacologica Sinica;2024-06-04

3. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma;Journal of Clinical Oncology;2023-08-20

4. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway;Acta Pharmaceutica Sinica B;2023-03

5. Upregulation of miR-101-3p Overcomes Ibrutinib Resistance by Targeting ABCC5 in Diffuse Large B-Cell Lymphoma (DLBCL);Journal of Hard Tissue Biology;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3